ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
CD47 is a widely expressed cell surface protein that functions as an immune checkpoint in cancer. When expressed by tumor cells, CD47 can bind SIRPα on myeloid cells, leading to suppression of tumor cell phagocytosis and other innate immune functions. CD47-SIRPα signaling has also been implicated in the suppression of adaptive antitumor responses, but the relevant cellular functions have yet to be elucidated. Therapeutic blockade of the CD47 pathway may stimulate antitumor immunity and improve cancer therapy. To this end, a novel CD47-blocking molecule, ALX148, was generated by fusing a modified SIRPα D1 domain to an inactive human IgG1 Fc. ALX148 binds CD47 from multiple species with high affinity, inhibits wild type SIRPα binding, and enhances phagocytosis of tumor cells by macrophages. ALX148 has no effect on normal human blood cells in vitro or on blood cell parameters in rodent and non-human primate studies. Across several murine tumor xenograft models, ALX148 enhanced the antitumor activity of different targeted antitumor antibodies. Additionally, ALX148 enhanced the antitumor activity of multiple immunotherapeutic antibodies in syngeneic tumor models. These studies revealed that CD47 blockade with ALX148 induces multiple responses that bridge innate and adaptive immunity. ALX148 stimulates antitumor properties of innate immune cells by promoting dendritic cell activation, macrophage phagocytosis, and a shift of tumor-associated macrophages toward an inflammatory phenotype. ALX148 also stimulated the antitumor properties of adaptive immune cells, causing increased T cell effector function, pro-inflammatory cytokine production, and a reduction in the number of suppressive cells within the tumor microenvironment. Taken together, these results show that ALX148 binds and blocks CD47 with high affinity, induces a broad antitumor immune response, and has a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 1×
“Digital images were taken with a AxioCam Hrm (Zeiss) and digitally merged using Fiji software [50].”
MethodHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“In the tumor, tumor-associated macrophages (TAMs) have pro-inflammatory (M1) and suppressive (M2) activities [52, 53].”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“In the tumor, tumor-associated macrophages (TAMs) have pro-inflammatory (M1) and suppressive (M2) activities [52, 53].”
BackgroundMerad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309 · cited 1×
“mary DC subset responsible for cross-priming of cytotoxic T cells [62].”
BackgroundNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970 · cited 1×
“CD47 is expressed on the surface of a broad range of cell types [9, 10], and this expression protects healthy cells from macrophage-mediated phagocytosis by interacting with its receptor, signal regulatory protein-α (SIRPα) [11, 12].”
BackgroundMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · cited 1×
“Similarly, CD47 blockade in mouse studies inhibits the growth of human tumor xenografts and promotes survival [22, 24, 25, 30, 33].”
BackgroundWillingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666 · cited 2×
“Similarly, CD47 blockade in mouse studies inhibits the growth of human tumor xenografts and promotes survival [22, 24, 25, 30, 33].”
BackgroundCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581 · cited 2×
“The CD47 pathway is an additional checkpoint that can suppress antitumor immunity [5, 6].”
BackgroundShields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087 · cited 2×
“Similarly, CD47 blockade in mouse studies inhibits the growth of human tumor xenografts and promotes survival [22, 24, 25, 30, 33].”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Integrin-associated protein (CD47) and its ligands
Brown, E. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01906-1 · Cited by 878 · cited 1×
“CD47 is expressed on the surface of a broad range of cell types [9, 10], and this expression protects healthy cells from macrophage-mediated phagocytosis by interacting with its receptor, signal regulatory protein-α (SIRPα) [11, 12].”
BackgroundCD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767 · cited 3×
“Previous studies have relied upon in vitro differentiated macrophages and DCs to demonstrate that in response to CD47 blockade these cells process tumor antigen and present them for priming of cytotoxic T cells [34, 36].”
Development and Function of Dendritic Cell Subsets
Mildner, A., & Jung, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.016 · Cited by 767 · cited 2×
“Although the role of CD8 DCs is not well characterized, they are thought to be superior to CD8 DCs for CD4 T cell priming [63].”
BackgroundTseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O’Rourke, T., Narayanan, S., Papadopoulos, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02018 · Cited by 599
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Phagocytosis and antigen presentation in dendritic cells
Savina, A., & Amigorena, S. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00552.x · Cited by 561 · cited 1×
“Because DCs play a particularly important role in naïve T cell activation and initiation of antigen-specific immune responses [54, 55], we investigated the effect of ALX148 on these cells in tumor-bearing mice.”
BackgroundThe CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557 · cited 1×
“In contrast to previously identified checkpoint pathways that target the adaptive arm of the immune response, this pathway suppresses the activity of innate immune cells [7, 8].”
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495 · cited 7×
“ALX148 was developed based upon the finding that phagocytosis can be enhanced by a combination approach in which CD47 blockade and Fcγ receptor engagement come from different molecules [32].”
BackgroundMethodResultInfluentialTsai, R. K., & Discher, D. E. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708043 · Cited by 486
Functions and molecular mechanisms of the CD47–SIRPα signalling pathway
Matozaki, T., Murata, Y., Okazawa, H., & Ohnishi, H. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.12.001 · Cited by 475
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475 · cited 4×
“The pharmacokinetic and pharmacodynamic properties of ALX148 are consistent with that of an anti-CD47 antibody observed in NHP [31] and support a weekly or biweekly dosing frequency in human patients.”
BackgroundInfluentialCd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis
Oldenborg, P.-A., Gresham, H. D., & Lindberg, F. P. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.855 · Cited by 452
Fujioka, Y., Matozaki, T., Noguchi, T., Iwamatsu, A., Yamao, T., Takahashi, N., Tsuda, M., Takada, T., & Kasuga, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6887 · Cited by 448
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9730 · Cited by 388
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366 · cited 1×
“The activation of T cells by PD-L1 inhibition was required to maximize the effect of CD47-SIRPα disruption [39].”
BackgroundCancer immunotherapy targeting the CD47/SIRPα axis
Weiskopf, K. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.013 · Cited by 353 · cited 2×
“For this reason, a variety of antibodies and fusion proteins targeting the CD47 pathway are in clinical development [30, 31, 40].”
BackgroundTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335 · cited 1×
“To investigate this hypothesis, CD4 and CD8 T cell populations were evaluated in the spleens of tumor bearing mice that received ALX148 alone or in combination with anti-PD-1, which activates adaptive T cell responses by inhibition of the PD-1 checkpoint [56].”
BackgroundZhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Xu, M. M., Pu, Y., Han, D., Shi, Y., Cao, X., Liang, H., Chen, X., Li, X.-D., Deng, L., Chen, Z. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.016 · Cited by 315
Seiffert, M., Cant, C., Chen, Z., Rappold, I., Brugger, W., Kanz, L., Brown, E. J., Ullrich, A., & Bühring, H.-J. (1999) · Blood · doi:10.1182/blood.v94.11.3633 · Cited by 303 · cited 1×
“CD47 is expressed on the surface of a broad range of cell types [9, 10], and this expression protects healthy cells from macrophage-mediated phagocytosis by interacting with its receptor, signal regulatory protein-α (SIRPα) [11, 12].”
BackgroundNegative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System
Okazawa, H., Motegi, S.-I., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., Oldenborg, P.-A., Ishikawa, O., & Matozaki, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2004 · Cited by 302
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.-P., George, B. M., Lietzenmayer, M., McKenna, K. M., Naik, T. J., McCarty, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710877114 · Cited by 283 · cited 1×
“CD47 blockade can also enhance neutrophil-mediated ADCC of cells bound by an active Fc [6, 60].”
BackgroundPetrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1700 · Cited by 278 · cited 3×
“Similarly, CD47 blockade in mouse studies inhibits the growth of human tumor xenografts and promotes survival [22, 24, 25, 30, 33].”
BackgroundZhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106550108 · Cited by 276 · cited 2×
“The CD47 pathway is an additional checkpoint that can suppress antitumor immunity [5, 6].”
BackgroundTao, M. H., Smith, R. I., & Morrison, S. L. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.661 · Cited by 251 · cited 1×
“No complement C1q binding was observed for ALX148 or the negative control protein ALX217, which contains an IgG4 Fc that has no complement C1q binding activity [51].”
BackgroundIn Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Xu, D., Alegre, M.-L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 238
Selby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231 · cited 1×
“The combination leads to an increase in IFNγ expressing CD8+ T cells upon stimulation while the number of tumor-specific CD8+ T cells remained similar, as in a previously reported study of checkpoint inhibitor combinations [57].”
ResultSoto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., Berzofsky, J. A., & Roberts, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0037-t · Cited by 195
Is CD47 an innate immune checkpoint for tumor evasion?
Liu, X., Kwon, H., Li, Z., & Fu, Y.-X. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0381-z · Cited by 185
CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1
Vernon-Wilson, E. F., Kee, W.-J., Willis, A. C., Barclay, A. N., Simmons, D. L., & Brown, M. H. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:18<2130::aid-immu2130>3.0.co;2-p · Cited by 176
Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor
Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia, G. A., & Myszka, D. G. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.08.005 · Cited by 166
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Xiao, Z., Chung, H., Banan, B., Manning, P. T., Ott, K. C., Lin, S., Capoccia, B. J., Subramanian, V., Hiebsch, R. R., Upadhya, G. A., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.036 · Cited by 164 · cited 1×
“Similarly, CD47 blockade in mouse studies inhibits the growth of human tumor xenografts and promotes survival [22, 24, 25, 30, 33].”
BackgroundMawby, W. J., Holmes, C. H., Anstee, D. J., Spring, F. A., & Tanner, M. J. A. (1994) · Biochemical Journal · doi:10.1042/bj3040525 · Cited by 156 · cited 1×
“CD47 is expressed on the surface of a broad range of cell types [9, 10], and this expression protects healthy cells from macrophage-mediated phagocytosis by interacting with its receptor, signal regulatory protein-α (SIRPα) [11, 12].”
BackgroundAnti-SIRPα antibodies as a potential new tool for cancer immunotherapy
Yanagita, T., Murata, Y., Tanaka, D., Motegi, S.-I., Arai, E., Daniwijaya, E. W., Hazama, D., Washio, K., Saito, Y., Kotani, T., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89140 · Cited by 153 · cited 1×
“TAM repolarization is apparently independent of which arm of the CD47-SIRPα interaction is targeted, as this phenotype was also described for mice treated with an antibody against SIRPα in a RENCA tumor model [69].”
BackgroundA Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis
Zaynagetdinov, R., Sherrill, T. P., Polosukhin, V. V., Han, W., Ausborn, J. A., McLoed, A. G., McMahon, F. B., Gleaves, L. A., Degryse, A. L., Stathopoulos, G. T., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100558 · Cited by 147
Herter, S., Birk, M. C., Klein, C., Gerdes, C., Umana, P., & Bacac, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301249 · Cited by 143
Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J. M., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120502 · Cited by 137
Munn, D. H., & Cheung, N. K. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.231 · Cited by 126
CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer
Yoshida, K., Tsujimoto, H., Matsumura, K., Kinoshita, M., Takahata, R., Matsumoto, Y., Hiraki, S., Ono, S., Seki, S., Yamamoto, J., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.478 · Cited by 125
Yi, T., Li, J., Chen, H., Wu, J., An, J., Xu, Y., Hu, Y., Lowell, C. A., & Cyster, J. G. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.021 · Cited by 113
Morgan, A. A., Jones, N. D., Nesbitt, A. M., Chaplin, L. C., Bodmer, M., & Emtage, J. S. (1995) · PubMed Central · Cited by 103
Kwong, L. S., Brown, M. H., Barclay, A. N., & Hatherley, D. (2014) · Immunology · doi:10.1111/imm.12290 · Cited by 95
Alblas, J., Honing, H., de Lavalette, C. R., Brown, M. H., Dijkstra, C. D., & van den Berg, T. K. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7181-7192.2005 · Cited by 89
Hatherley, D., Harlos, K., Dunlop, D. C., Stuart, D. I., & Barclay, A. N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611511200 · Cited by 86 · cited 2×
“ALX148 is comprised of the N-terminal D1 domain of SIRPα, which binds CD47 [43, 44], fused to a modified human IgG1 Fc domain.”
BackgroundOghumu, S., Varikuti, S., Terrazas, C., Kotov, D., Nasser, M. W., Powell, C. A., Ganju, R. K., & Satoskar, A. R. (2014) · Immunology · doi:10.1111/imm.12293 · Cited by 84
Oflazoglu, E., Stone, I. J., Brown, L., Gordon, K. A., van Rooijen, N., Jonas, M., Law, C.-L., Grewal, I. S., & Gerber, H.-P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604812 · Cited by 81
Dichotomous miR expression and immune responses following primary blood-stage malaria
Burel, J. G., Apte, S. H., Groves, P. L., Boyle, M. J., Langer, C., Beeson, J. G., McCarthy, J. S., & Doolan, D. L. (2017) · JCI Insight · doi:10.1172/jci.insight.93434 · Cited by 70
A novel MyD-1 (SIRP-1α) signaling pathway that inhibits LPS-induced TNFα production by monocytes
Smith, R. E., Patel, V., Seatter, S. D., Deehan, M. R., Brown, M. H., Brooke, G. P., Goodridge, H. S., Howard, C. J., Rigley, K. P., Harnett, W., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3596 · Cited by 69
Dong, L., Kong, X., Yan, H., Yu, L., Chen, L., Yang, W., Liu, Q., Huang, D., Wu, M., & Wang, H. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.03.012 · Cited by 60
Dual Regulation of SIRPα Phosphorylation by Integrins and CD47
Johansen, M. L., & Brown, E. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701565200 · Cited by 59
Cited by
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Zhang, W., Huang, Q., Xiao, W., Zhao, Y., Pi, J., Xu, H., Zhao, H., Xu, J., Evans, C. E., & Jin, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00018 · Cited by 353
Targeting CD47 for cancer immunotherapy
Jiang, Z., Sun, H., Yu, J., Tian, W., & Song, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01197-w · Cited by 346
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
Metadata
- Authors
- Kauder, S. E., Kuo, T. C., Harrabi, O., Chen, A., Sangalang, E., Doyle, L., Rocha, S. S., Bollini, S., Han, B., Sim, J., Pons, J., & Wan, H. I.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-08-22
- Volume
- 13
- Issue
- 8
- Pages
- e0201832
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2888609501
- Cited by
- 168
- References
- 71
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.